Skip to main
CORT

Corcept Therapeutics (CORT) Stock Forecast & Price Target

Corcept Therapeutics (CORT) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 25%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Corcept Therapeutics has demonstrated a strong financial trajectory, with risk-adjusted sales projections increasing from $171 million in 2026 to peak sales of $1.9 billion by 2031, reflecting significant growth potential within its oncology pipeline. The recent FDA approval of relacorilant following positive survival data from the ROSELLA trial enhances market penetration expectations for ovarian cancer therapies, raising the anticipated market share from 20% to 25%. Additionally, the company plans to bolster its sales efforts with a dedicated team of 50 oncology sales representatives, further supporting operational growth and the potential for expansive revenue generation in the coming years.

Bears say

Corcept Therapeutics has seen a significant downgrade in its 12-month price target, dropping from $105 to $67 per diluted share, primarily due to anticipated pricing pressures on Korlym sales, which may decline due to increased discounts for its generic version and potential regulatory changes. The company's outlook has been further complicated by a Complete Response Letter (CRL) for relacorilant in Cushing's syndrome, leading to a substantial decline in share prices and concerns regarding management turnover that could hinder clinical development progress. Additionally, the increase in the discount rate from 10% to 12% highlights elevated execution risks, further exacerbating the negative financial outlook for the company.

Corcept Therapeutics (CORT) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 25% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Corcept Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Corcept Therapeutics (CORT) Forecast

Analysts have given Corcept Therapeutics (CORT) a Buy based on their latest research and market trends.

According to 4 analysts, Corcept Therapeutics (CORT) has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $96.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $96.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Corcept Therapeutics (CORT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.